1H: Biomaterials in Engineering the Tumor Immune Microenvironment
Timeslot: Wednesday, April 19, 2023 - 1:00pm to 2:30pm
Room: Shorebreak
About
Malignant cells of the tumor co-exist with non-malignant cells in a 3D space. Immune cells of many types such as macrophages, dendritic cells, mast cells, T-cells and more make up the tumor immune microenvironment (TIME). Biomaterials are incorporated in bioengineering the TIME for multiple purposes: (1) creating bioengineered models to further fundamental immuno-oncology studies; and (2) modulating anti-tumor immune response. Cancer-immune cell interactions in the TIME are specifically important to study for the development of immunotherapies to treat various types of cancer. Not only is engineering the TIME useful for drug discovery, it can also provide mechanistic insights into cancer-immune cell interactions within the TIME that can be used to develop targeted immuno-therapies.
In this session, we will explore all aspects of biomaterials used to engineer or modulate the tumor immune microenvironment.
1:00 PM 44. INVITED SPEAKER. Activation of Adaptive and Innate Immune Cells via Localized Cytokine Delivery for Cancer Immunotherapy.
1:30 PM. 45. Engineered Macrophages eliminate Solid Tumors and initiate Anti-tumor Immunity. Prof. Dennis Discher. University of Pennsylvania.
1:45 PM. 46. Conjugated STING-agonist nanoparticles enhance antitumor immunity in multiple tumor models. Dr. Pere Dosta Pons, Dr. Alexander Cryer, Michelle Dion, Dr. Tsubasa Shiraishi, Dr. Steven Langston, Dr. David Lok, Michaela Prado, Alma Rodriguez, Dr. Adnan Abu-Yousif, Dr. Natalie Artzi. Brigham and Women's Hospital, Massachusetts Institute of Technology, Takeda Development Center Americas, Inc.
2:00 PM 47. Multi-niche Human Bone Marrow On-A-Chip for Studying Interactions of Cell Therapies With Multiple Myeloma. Delta Ghoshal, Abel Thomas, Ingrid Peterson, Prof. Krishnendu Roy. Georgia Institue of Technology.
2:15 PM 48. Multi-omics Guided Design of Biomaterials-based Lymphoid Tissues to Study BCR-TLR Signaling in Lymphomas. Ankur Singh, Christopher Carlson, Dr. Shivem Shah, Zhe Zhong, Mayar Allam, Lauren Walter, Karen Martin, Benjamin Cogrove, Andres Garcia, Ahmet Coskun, Jean Koff. Georgia Institute of Technology, Cornell University, Emory University.